Share your opinion and earn yourself a free Motley Fool premium report!

We are looking for Fools to join a 75 minute online independent market research forum on 15th / 16th December.

To find out more and express your interest please click here

I just bought these beaten-up growth stocks for my ISA

Edward Sheldon just snapped up two new stocks for his ISA. Both are currently well off their 52-week highs, meaning their valuations have also come down.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Right now, there are many stocks well off their recent highs. As a result, I’m seeing quite a few attractive investment opportunities.

Here, I’m going to highlight two stocks I’ve snapped up for my ISA in the last few weeks. Both have taken a big hit recently and I see the potential for a rebound.

A buying opportunity

First up is Ergomed (LSE: ERGO). It’s an under-the-radar, founder-led company that provides specialised services to the pharma industry. Operating in over 100 countries, it offers solutions to project management (for drug trials, etc), clinical monitoring, regulatory affairs, and more.

Ergomed’s share price has come down from near 1,400p to around 1,000p since the start of December and I see a lot of appeal in the stock after the fall.

This is a healthcare company that has a fair bit of momentum right now. Last year, the group generated revenue of £145.3m, up 22.5% year on year. And at the end of 2022, the group’s order book was sitting at a £295m record high.

As we look ahead to 2023, demand for our services is high.

Dr Miroslav Reljanović, Ergomed Executive Chairman

The risk here is that funding for biotech customers could dry up if financial conditions continue to tighten. This could impact the stock – which currently has a price-to-earnings (P/E) ratio of about 22 – in the short term.

Taking a long-term view however, I’m confident in the growth story. Over the next decade, the global drug discovery market is projected to grow at around 9% per year.

Huge growth potential

Another stock I bought was Airbnb (NASDAQ: ABNB), which is listed in the US. It operates the world’s largest home rental platform.

There’s a lot to like about this well-known company from an investment perspective, in my view. It has a great product/service for a start. I was reminded of this when I recently took a trip to Australia. Through Airbnb, I was able to find some top-notch accommodation.

Secondly, it has a very powerful brand, so powerful that it has even become a verb. This is a huge competitive advantage.

Third, the company has plenty of growth potential. The beauty of its platform is that it’s really scalable. I see the company as well-placed to benefit from the retirement of the Baby Boomers (who love to travel).

Looking forward to 2023, we’re seeing strong demand in Q1, indicating that consumer confidence to travel remains high.

Airbnb 2022 results

Finally, the company is now profitable. This year, the group is projected to generate earnings per share of $3.30.

Now ,Airbnb shares are well off their 52-week highs. This time last year, they were trading near $165. Today, they’re near $110.

Yet even after this share price weakness, they’re still quite expensive. Currently, the forward-looking P/E ratio here is about 33. This adds risk to the investment case.

I’m convinced that buying now will pay off in the long run though. I think this travel company is just getting started.

Edward Sheldon has positions in Airbnb and Ergomed Plc. The Motley Fool UK has recommended Airbnb and Ergomed Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

Forget high yields? Here’s the smart way to build passive income with dividend shares

Stephen Wright outlines how investors looking for passive income can put themselves in the fast lane with dividend shares.

Read more »

Businessman hand stacking up arrow on wooden block cubes
Investing Articles

15,446 Diageo shares gets me a £1,000 monthly second income. Should I?

Diageo has been a second-rate income stock for investors over the last few years. But the new CEO sees potential…

Read more »

Investing Articles

2 FTSE 100 stocks to target epic share price gains in 2026!

Looking for blue-chip shares to buy? Discover which two FTSE 100 stocks our writer Royston Wild thinks could explode in…

Read more »

A row of satellite radars at night
Investing Articles

If the stock market crashes in 2026, I’ll buy these 2 shares like there’s no tomorrow

These two shares have already fallen 25%+ in recent weeks. So why is this writer wating for a stock market…

Read more »

British Pennies on a Pound Note
Investing Articles

How much money does someone really need to start buying shares?

Could it really be possible to start buying shares with hundreds of pounds -- or even less? Christopher Ruane weighs…

Read more »

Two gay men are walking through a Victorian shopping arcade
Investing Articles

With Versace selling for £1bn, what does this tell us about the valuations of the FTSE 100’s ‘fashionable’ stocks?

Reflecting on the sale of Versace, James Beard reckons the valuations of the FTSE 100’s fashion stocks don’t reflect the…

Read more »

A senior group of friends enjoying rowing on the River Derwent
Investing Articles

Want to stuff your retirement portfolio with high-yield shares? 5 to consider that yield 5.6%+

Not everyone wants to have a lot of high-yield shares in their portfolio. For those who might, here's a handful…

Read more »

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

How much do you need in a SIPP to target a £3,658 monthly passive income?

Royston Wild discusses a 9.6%-yielding fund that holds global stocks -- one he thinks could help unlock an enormous income…

Read more »